Search

Veracyte Inc

Cerrado

SectorSanidad

58.59 -0.39

Resumen

Variación precio

24h

Actual

Mínimo

54.83

Máximo

59.68

Métricas clave

By Trading Economics

Ingresos

-20M

29M

Ventas

-1.6M

139M

P/B

Media del Sector

52.125

60.149

BPA

0.52

Margen de beneficios

20.642

Empleados

755

EBITDA

-11M

35M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+3.04% upside

Dividendos

By Acuity

Próximas Ganancias

30 jul 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

1.8B

4.5B

Apertura anterior

58.98

Cierre anterior

58.59

Veracyte Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 jul 2026, 17:16 UTC

Correlated Moves

Veracyte Inc shares are higher today, recovering after three days of declines. The stock is now above its 20-day moving average.

20 jul 2026, 20:01 UTC

Correlated Moves

Veracyte Inc shares declined sharply today, marking three consecutive lower sessions amid broader market weakness and heightened volatility related to geopolitical tensions.

Comparación entre iguales

Cambio de precio

Veracyte Inc previsión

Precio Objetivo

By TipRanks

3.04% repunte

Estimación a 12 Meses

Media 59 USD  3.04%

Máximo 70 USD

Mínimo 47 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Veracyte Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

10 ratings

8

Comprar

1

Mantener

1

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Veracyte Inc

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.